NTQ1062 is an oral ATP-competitive Akt inhibitor being developed for cancer. The IC50 of Akt1, Akt2 and Akt3 were 0.4 nM, 6.3 nM and 0.1 nM, respectively. Apoptosis induced by NTQ1062 resulted in cell cycle arrest at G0/G1 phase. NTQ1062 has anti-proliferation activity against a variety of cancer cells. NTQ1062 showed potent antitumor effects in the LNCap xenograft tumor mouse model.
Molecular Weight | 483.01 |
Formula | C25H31ClN6O2 |
CAS Number | 2459489-66-6 |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related Akt Products |
---|
LY2780301
LY2780301 is an oral dual-target inhibitor of AKT/RSK that binds to and inhibits the activity of Akt, thereby inhibiting the PI3K/Akt signaling pathway, which in turn inhibits cell proliferation and induces apoptosis in tumor cells, and possesses antitumor activity. |
Akt/SKG Substrate Peptide
Akt/SKG Substrate Peptide is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1. |
Adropin (34-76) (human, mouse, rat)
Adropin (34-76) (human, mouse, rat) regulates fuel selection preferences in skeletal muscle. |
Apoptin-derived peptide
Apoptin-derived peptide is an antitumor polypeptide with cytotoxicity. |
TAT-TCL1-Akt-in
TAT-TCL1-Akt-in is an Akt inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.